Pemphigoid gestationis: current insights into pathogenesis and treatment

Area of Science:

• Immunodermatology
• Reproductive Immunology
• Autoimmune Diseases

Background:

• Pregnancy involves maternal-fetal immune tolerance, which can be disrupted in certain conditions.
• Pemphigoid gestationis (PG) is an autoimmune subepidermal bullous dermatosis occurring during pregnancy.
• It arises from an immune response against placental proteins, specifically collagen XVII, due to cross-reactivity with skin antigens.

Purpose of the Study:

• To review the current understanding of Pemphigoid gestationis (PG).
• To present the latest scientific and clinical data on PG pathogenesis and treatment.
• To highlight the need for further research into PG's pathogenic cascade and therapeutic targets.

Main Methods:

• Review of existing literature on Pemphigoid gestationis.
• Analysis of immunofluorescence findings (linear C3/IgG deposition along the basement membrane zone).
• Discussion of clinical presentation, diagnosis, and treatment based on case reports and clinical experience.

Main Results:

• Pemphigoid gestationis involves maternal antibodies against collagen XVII, exposed via aberrant MHC class II expression in the placenta.
• Genetic predisposition (HLA genotype) and antigen presentation trigger inflammation and the characteristic skin lesions.
• The disease typically resolves postpartum but can recur in subsequent pregnancies.

Conclusions:

• Pemphigoid gestationis pathogenesis involves a complex interplay of genetic predisposition, immune recognition of placental collagen XVII, and inflammation.
• Current treatment relies mainly on oral corticosteroids, with limited options for recalcitrant cases.
• Further research is crucial to elucidate pathogenic mechanisms and develop targeted therapies for Pemphigoid gestationis.